HF
ALNA

HRT Financial’s Allena Pharmaceuticals ALNA Stock Holding History

HRT Financial’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,382
Closed -$31K – 3773
2021
Q1 		$31K Buy
+22,382
New +$37.3K ﹤0.01% 2575

Other funds holding ALNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

HRT Financial's ALNA Position: Q2 2021 in Review

HRT Financial sold out of Allena Pharmaceuticals (ALNA) in Q2 2021, closing a stake of 22,382 shares — an estimated $31K sold.

HRT Financial first reported a position in ALNA in Q1 2021 and held it in 1 quarter. The position peaked at $31K in Q1 2021. 29 funds tracked by Wall St. Rank hold ALNA as of Q2 2021.

  • HRT Financial reported no remaining Allena Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HRT Financial sold 22,382 Allena Pharmaceuticals shares in Q2 2021, an estimated $31K.
  • HRT Financial first reported a position in Allena Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • HRT Financial's Allena Pharmaceuticals position peaked at $31K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2021.

Based on HRT Financial's 13F filing for Q2 2021, filed 16 Aug 2021.